Using a virus to deliver antibodies that protect against SIV infection
Official title: Protection against Mucosal SIV Challenge by Adeno-Associated Virus Delivery of Env-Specific Antibodies
Funded at Bioqual, INC. · NIH-10927011 · Data updated 2026-11-12
This study is looking at a new way to help protect against the Simian Immunodeficiency Virus (SIV) by using special antibodies delivered through a harmless virus, and it's being tested in nonhuman primates to find better strategies for future HIV vaccines and treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bioqual, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $1,999,460 |
| NIH project number | 75N93020D00006-0-759302300001-1 |
| Project ID | NIH-10927011 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for HIV infection who may benefit from innovative preventive strategies.
✕Less likely to help
Patients who are already HIV positive or those with existing immune deficiencies may not benefit from this research.
What this research studies
This research focuses on developing a method to protect against Simian Immunodeficiency Virus (SIV) by delivering specific antibodies through Adeno-Associated Virus (AAV) technology. The approach involves using nonhuman primates to evaluate how well these antibodies can prevent or control viral infections. By studying immune responses in these models, researchers aim to identify effective strategies for future HIV vaccines and treatments. The research will also explore ways to enhance the effectiveness of these vaccines through thorough testing and evaluation.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing HIV infection in humans.
How similar studies have gone: Previous research has shown promise in using similar viral delivery methods for vaccine development, indicating potential for success in this approach.
Where this research is happening
-
Bioqual, INC.
Rockville, United States Active
Researchers
- Principal investigator: Ferrari, Maria — Bioqual, INC.
- Study coordinator: Ferrari, Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.